Effects of Groviva on growing children.
Phase 4
- Registration Number
- CTRI/2024/02/063252
- Lead Sponsor
- Signtura Health and nutrition
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
o Male or female aged between 2 to 12 years.
o Subjects or their representatives must sign with date an informed consent prior to any evaluation and participation in the trial.
o Healthy child with BMI below 15th percentile
Exclusion Criteria
o Child suffering from diarrhea, serious medical condition, hormonal disorder
o Participation in another trial with another investigational product.
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does Groviva target to influence pediatric growth and development in CTRI/2024/02/063252?
How does Groviva's efficacy in 2-12 year-olds compare to standard nutritional interventions for growth disorders?
Are there specific biomarkers identified in CTRI/2024/02/063252 to predict Groviva response in children with developmental delays?
What adverse events were monitored in the post-marketing real-world study of Groviva for pediatric health (CTRI/2024/02/063252)?
What nutraceutical compounds or combination therapies are being evaluated alongside Groviva for pediatric growth optimization in Signtura Health trials?